Guided Therapeutics Net debt/EBITDA
What is the Net debt/EBITDA of Guided Therapeutics?
The Net debt/EBITDA of Guided Therapeutics, Inc. is -0.52
What is the definition of Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA of companies in the Health Care sector on OTC compared to Guided Therapeutics
What does Guided Therapeutics do?
Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.
Companies with net debt/ebitda similar to Guided Therapeutics
- Visteon has Net debt/EBITDA of -0.52
- Bouvet ASA has Net debt/EBITDA of -0.52
- TOT BIOPHARM International has Net debt/EBITDA of -0.52
- Coolpad has Net debt/EBITDA of -0.52
- Franchise International has Net debt/EBITDA of -0.52
- Vanadiumcorp Resource has Net debt/EBITDA of -0.52
- Guided Therapeutics has Net debt/EBITDA of -0.52
- Mandalay Resources has Net debt/EBITDA of -0.52
- Midnight Sun Mining has Net debt/EBITDA of -0.51
- Sonoro Gold has Net debt/EBITDA of -0.51
- McEwen Mining has Net debt/EBITDA of -0.51
- SKY Network Television has Net debt/EBITDA of -0.51
- Old Dominion Freight Line has Net debt/EBITDA of -0.51